Comparison of peptide production technologies used by industry leaders

Industry leaders manufacture peptides using four main technologies: solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), hybrid solid-liquid synthesis, and enzymatic synthesis. SPPS dominates research-grade and most therapeutic production. LPPS handles short peptides at industrial scale. Hybrid combines both for long and complex sequences. Enzymatic methods are emerging as a greener alternative for longer chains. The right method depends on length, scale, purity targets, and cost per gram.

Why peptide production technology matters

The choice of synthesis route directly affects purity, yield, scalability, and cost per gram - which in turn shape whether a peptide becomes a research compound, a clinical candidate, or a commercial drug. Leading manufacturers don't pick one method; they match the method to the molecule.

1. Solid-phase peptide synthesis (SPPS)

SPPS, introduced by Bruce Merrifield in 1963, anchors a growing peptide chain to an insoluble resin while reagents wash through. It is the workhorse of the industry.

Best for: peptides up to roughly 50 amino acids.

Strengths: automation-friendly; high coupling efficiency; microwave-assisted SPPS now compresses cycles from hours to minutes, with crude purities above 90%.

Trade-offs: solvent-intensive; expensive for long sequences; resin and reagent costs scale linearly.

Used by: most research-grade suppliers and the majority of FDA-approved peptide drugs.

2. Liquid-phase peptide synthesis (LPPS)

LPPS builds peptides in solution rather than on a resin. It predates SPPS and remains the method of choice for short peptides at industrial scale.

Best for: peptides under 10 amino acids and large-volume commercial runs.

Strengths: lower per-gram cost at scale; better solvent recovery; no resin bottleneck.

Trade-offs: requires intermediate isolation and purification steps; slower for long chains; more complex process development.

3. Hybrid synthesis

Hybrid synthesis splits a long peptide into fragments each made by SPPS, then ligates the fragments in solution using LPPS.

Best for: peptides over 50 amino acids and complex therapeutics, including enfuvirtide and certain GLP-1 analogues.

Strengths: balances the speed of SPPS with the scale economics of LPPS; enables sequences too long for either method alone.

Trade-offs: more process steps; requires careful ligation chemistry.

4. Enzymatic and cell-free synthesis

Enzymatic synthesis uses peptide ligases or proteases to form peptide bonds in aqueous conditions. Cell-free systems use ribosomes outside living cells.

Best for: long peptides, "green" production, and sequences with challenging post-translational modifications.

Strengths: significantly lower solvent waste; water-based chemistry; specific modifications can be introduced enzymatically.

Trade-offs: still scaling up commercially; enzyme costs and substrate specificity remain limiting factors.

Status: capacity investments from CDMOs like CordenPharma signal this is the direction the industry is moving for next-generation peptides.

How industry leaders actually choose

The decision usually comes down to four variables: sequence length, required purity, batch size, and modification complexity. A short, well-known peptide at scale goes through LPPS. A research peptide or therapeutic candidate under 50 residues uses SPPS. A complex 60+ amino acid drug uses a hybrid. Enzymatic is increasingly considered for sustainability and for sequences that resist conventional chemistry.

For researchers evaluating supplier output, whether for academic work or formulation R&D, the production method behind a product directly shapes its purity profile and impurity fingerprint. This is why transparent suppliers, including peptide research solutions providers like NuScience Peptides, publish HPLC traces and mass-spec confirmation against each batch.

What this means for buyers and researchers

• For drug developers: hybrid and enzymatic are where investment is flowing.
• For research labs: SPPS-produced material with batch-level COAs remains the safest bet.
• For manufacturers: production method is no longer a back-office detail, it is increasingly a marketing and regulatory signal.

Frequently asked questions

Which peptide production method is most common today?

SPPS handles the largest share of research and clinical-stage peptides because it scales well from milligrams to kilograms and pairs cleanly with modern automation.

Why don't industry leaders use just one method?

Because the optimal route depends on the molecule. SPPS handles up to roughly 50 amino acids efficiently; longer or commercial-scale work usually requires LPPS or hybrid synthesis.

Is enzymatic peptide synthesis ready for commercial production?

For specific peptides, yes particularly where green chemistry or unusual modifications matter. For most catalog peptides, SPPS still wins on cost and predictability in 2026.